Abstract 2121P
Background
Recently, the development of anticancer drug administration methods and advances in supportive care for side effects have made it possible to safely perform chemotherapy through outpatient visits. Outpatient chemotherapy is important for maintaining the patient's quality of life (QOL). Side effects of chemotherapy include anorexia, nausea, dysgeusia, and oral mucosal disorders, which affect diet, and weight loss affecting the effectiveness and prognosis. In particular, patients with gastrointestinal cancer are considered to have a high nutritional risk status. We assessed the nutritional status of patients with gastrointestinal cancer during outpatient chemotherapy and found an association with adverse events symptoms.
Methods
The Tohoku University School of Medicine IRB approved this study (2018-1-176); patients provided written informed consent. Patients undergoing outpatient chemotherapy were enrolled, nutritional status, self-assessment of adverse events and depression by The Depression Scale Epidemiological Research Center (CES-D) were assessed. Responses were analyzed by Chi-squared test, ANOVA, Spearman's correlation coefficient, and multiple regression analysis. p<0.05 was considered significant. All statistical analyses were performed using SPSS (ver. 21).
Results
Valid responses were obtained from 120 patients with gastrointestinal cancers including pancreatic, colorectal, gastric, and esophageal cancers. The mean age was 65.2 (±9.6) years. Side effects of chemotherapy were fatigue in 99 (83.9%), neuropathy in 88 (73.3%), and dysgeusia in 85 (70.8%). Subjects were classified into 70 normal persons, 32 malnourished, 6 pre-cachexia, and 12 cachexia according to the nutrition assessment classification by Glasgow prognostic score (GPS). Although GPS classification did not show a significant relationship with the basic attributes, there was a significant relationship between anorexia (r=0.26, p=0.004), taste change (r=0.26, p=0.005), dry mouth (r=0.18, p=0.049), and edema (r=0.22, p=0.018).
Conclusions
Adverse events during chemotherapy including anorexia, dysgeusia, dry mouth and edema would have negative impact on nutritional status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
JSPS KAKENHI Grant Number JP 16K07140.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06